0.168
-0.02 (-9.79%)
| Penutupan Terdahulu | 0.186 |
| Jumlah Dagangan | 321,200 |
| Harga / Jualan (P/S) | 1.15 |
| Harga / Buku (P/B) | 0.780 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -330.18% |
| EPS Cair (TTM) | -2.80 |
| Nisbah Semasa (MRQ) | 2.55 |
| Aliran Tunai Operasi (OCF TTM) | -24.68 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -16.53 M |
| Pulangan Atas Aset (ROA TTM) | -915.19% |
| Pulangan Atas Ekuiti (ROE TTM) | -78,814.56% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | GeoVax Labs, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| Persekitaran Makro | -0.3 |
| AI Insight | NA |
| Purata | -0.69 |
|
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.42% |
| % Dimiliki oleh Institusi | 7.72% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |